Entremed (ENMD)

[nottadoc2]

And from Dr. Herbst, of MD Anderson, quoted:

"“We have arrived at a stage when creative clinical trial designs are becoming important. Although a combination approach of targeted agents with chemotherapy and radiotherapy is here to stay, the future of cancer therapy will be to combine antiangiogenic agents without chemotherapy and radiotherapy.”

This from the PI, if I recall correctly, of the "failed" phase 1 clinical trial of ES at MDA. Maybe Moberylane and I should cheer up. Glass might be looking half-full after all.